ArticleBreast (Edinburgh, Scotland)2019
Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study.
Article in Breast (Edinburgh, Scotland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Pooled it
- Recurrence of Head and Neck Squamous Cell Carcinoma: Did the COVID-19 Pandemic Have an Impact on Therapeutic Management?Journal of clinical medicine · 2025Article
- Alignment Between Treatment Decision and Treatment Administration for Squamous Cell Carcinoma of the Upper Aerodigestive Tract Before, During, and After the COVID-19 Pandemic: A Retrospective Analysis.Journal of clinical medicine · 2025Article
- Quality Indicators Compliance and Survival Outcomes in Breast Cancer according to Age in a Certified Center.Cancers · 2023Article
- Article
- Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attended.European journal of cancer care · 2022Article
- Breast Cancer Treatment in Integrated Care Process in Andalusia: The Challenge of Multidisciplinarity.International journal of environmental research and public health · 2022Article
- Impact of Competition Versus Centralisation of Hospital Care on Process Quality: A Multilevel Analysis of Breast Cancer Surgery in France.International journal of health policy and management · 2022Article
- Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?Frontiers in oncology · 2022Article
- Multidisciplinary team meeting as a highly recommended EUSOMA criteria evaluating the quality of breast cancer management between centers.Breast (Edinburgh, Scotland) · 2021Article
- Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.The oncologist · 2021Article
- Quality of Histopathological Reporting in Breast Cancer: Results From Four South African Breast Units.JCO global oncology · 2021Article
- Modern surgical treatment of breast cancer.Annals of medicine and surgery (2012) · 2020Review
- Comment on: "Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study".Breast (Edinburgh, Scotland) · 2020Article
- Evaluation of the breast cancer care network within the Lazio Region (Central Italy).PloS one · 2020Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe evaluate breast cancer (BC) pathway at a regional level including public, private and university institutions. We assessed the quality of multidisciplinary team meetings (MTM) and compliance with a panel of European high-quality indicators (EUSOMA QIs).
methodsWe conducted a retrospective multicenter (n = 20) study in the largest health care region in France. Between January and April 2015, we included all patients discussed at an MTM after a diagnosis of BC (n = 619). We analyzed quality of MTM by assessing the quorum, the reliability of data transcription and the exhaustivity of pre-therapeutic MTM. We then analyzed the compliance with a selected panel of 16 EUSOMA QIs.
resultsDuring MTM discussion, data were more than 95% consistent with medical records for 9/11 items. Pre-operative tumor histology (90.6%) and post-operative resection margins (84.3%) were the least concordant between medical records and MTM. Minimum standards as defined by EUSOMA were reached for 11/16 QIs, but not reached for pathology reports in non-invasive BC (78.2%), proportion of exclusive sentinel lymph node biopsies in patients with clinically negative axilla (85.2%), performing adjuvant chemotherapy (76.6%), and proportion of patients discussed in pre-therapeutic and post-operative MTM (63.5%).
conclusionsIn this multicentric study evaluating the quality of BC care with a representative sample of institutions, compliance with EUSOMA indicators was satisfactory for all type of institutions. However, too few patients were discussed in pre-therapeutic MTM (especially in non-university hospitals 43.7% [39.4-48.1]) versus 88.7% for others [82.2-95.1]) and data transcription was likely responsible for up to 15% of discordance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.